>>172795, >>172796, >>172797, >>172798, >>172799, >>172800, >>172801, >>172802, >>172803, >>172804, >>172805, >>172806, >>172807, >>172808, >>172809, >>172810, >>172811, >>172812, >>172813, >>172814, >>172815, >>172816, >>172817, >>172818, >>172819, >>172820, >>172821, >>172822, >>172823, >>172824, >>172825, >>172826, >>172827, >>172828, >>172829, >>172830, >>172831, >>172832, >>172833, >>172834, >>172835, >>172836, >>172837, >>172838, >>172839, >>172840, >>172841, >>172842, >>172843, >>172844, >>172845, >>172846, >>172847, >>172848, >>172849, >>172850, >>172851, >>172852, >>172853, >>172854, >>172855, >>172856, >>172857, >>172858, >>172859, >>172860, >>172861, >>172862, >>172863, >>172864, >>172865, >>172866, >>172867, >>172868, >>172869, >>172870, >>172871, >>172872, >>172873, >>172874, >>172875, >>172876, >>172877, >>172878, >>172879, >>172880, >>172881, >>172882, >>172883, >>172884, >>172885, >>172886, >>172887, >>172888, >>172889, >>172890, >>172891, >>172892, >>172893, >>172894, >>172895, >>172896, >>172897, >>172898, >>172899, >>172900, >>172901, >>172902, >>172903, >>172904, >>172905, >>172906, >>172907, >>172908, >>172909, >>172910, >>172911, >>172912, >>172913
It may help overcome drug resistance: When combined with tamoxifen (a standard hormone therapy), lower doses of tamoxifen still worked, hinting that Ivermectin could make resistant cancers sensitive again.
It reduces cancer spread potential: Cancer spreads (metastasizes) when cells become more mobile and invasive.
Ivermectin blocked the cancer cells’ ability to migrate and invade in lab tests.
It did this partly by reversing “epithelial-mesenchymal transition” (EMT)—a process where cancer cells become more aggressive and spread-prone.
Specifically, Ivermectin lowered levels of proteins like vimentin and snail (which promote spread) and may help restore E-cadherin (which keeps cells stuck together).
The paper focuses on the Wnt signaling pathway, which is often overactive in breast cancer and drives growth and spread.
Ivermectin reduced certain Wnt “signals” (like Wnt5a/b ligands) and a receptor (LRP6), leading to less EMT and potentially slower progression.
The effects were stronger in resistant cells.
The researchers compared Ivermectin to an approved drug palbociclib (Ibrance), used for similar resistant breast cancers, and found Ivermectin was more effective at blocking some spread-related changes in their tests.
CONCLUSION:
These lab results suggest Ivermectin has promising anti-growth and anti-spread effects on hormone-therapy-resistant breast cancer cells, possibly by interfering with the Wnt pathway and EMT.
My Take…
I always get asked - how can Ivermectin possibly treat cancer if it’s an anti-parasitic?
The answer is: Ivermectin is a LOT MORE than just an anti-parasitic.
Ivermectin has extensive anti-neoplastic properties!
@FLSurgeonGen